240 related articles for article (PubMed ID: 22801850)
1. Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity.
Harder BC; von Baltz S; Schlichtenbrede FC; Jonas JB
Arch Ophthalmol; 2012 Jun; 130(6):800-1. PubMed ID: 22801850
[No Abstract] [Full Text] [Related]
2. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.
Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB
Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab following laser therapy for severe retinopathy of prematurity.
Erol N; Gürsoy H; Sahin A; Basmak H
J Pediatr Ophthalmol Strabismus; 2010 Aug; 47 Online():e1-4. PubMed ID: 21158371
[TBL] [Abstract][Full Text] [Related]
4. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity.
Karaca C; Oner AO; Mirza E; Polat OA; Sahiner M
JAMA Ophthalmol; 2013 Aug; 131(8):1099-101. PubMed ID: 23744183
[No Abstract] [Full Text] [Related]
5. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
[TBL] [Abstract][Full Text] [Related]
6. A rare association of intravitreal bevacizumab injection with double ridge formation in retinopathy of prematurity.
Yaz Y; Erol N; Gursoy H; Basmak H; Bilgec MD
J Pediatr Ophthalmol Strabismus; 2014 Oct; 51 Online():e66-8. PubMed ID: 25333243
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity.
Moran S; O'Keefe M; Hartnett C; Lanigan B; Murphy J; Donoghue V
Acta Ophthalmol; 2014 Sep; 92(6):e496-7. PubMed ID: 24428792
[No Abstract] [Full Text] [Related]
8. Different refractive errors in triplets with retinopathy of prematurity treated with bevacizumab.
Tseng CC; Chen SN; Hwang JF; Lin CJ
J Pediatr Ophthalmol Strabismus; 2012 Aug; 49 Online():e41-3. PubMed ID: 22881829
[TBL] [Abstract][Full Text] [Related]
9. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity.
Kim J; Kim SJ; Chang YS; Park WS
Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184
[TBL] [Abstract][Full Text] [Related]
10. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study.
Kong L; Mintz-Hittner HA; Penland RL; Kretzer FL; Chévez-Barrios P
Arch Ophthalmol; 2008 Aug; 126(8):1161-3. PubMed ID: 18695118
[No Abstract] [Full Text] [Related]
11. Ultra-low dose of intravitreal bevacizumab in the treatment of retinopathy of prematurity.
Connor AJ; Papastavrou VT; Hillier RJ; Shafiq A
J Pediatr Ophthalmol Strabismus; 2015 Apr; 52 Online():e20-1. PubMed ID: 25942065
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Refractive Errors and Ocular Biometric Outcomes after Intravitreal Bevacizumab for Retinopathy of Prematurity.
Gunay M; Sekeroglu MA; Bardak H; Celik G; Esenulku CM; Hekimoglu E; Bardak Y
Strabismus; 2016 Jun; 24(2):84-8. PubMed ID: 27120579
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.
Wu WC; Lien R; Liao PJ; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
JAMA Ophthalmol; 2015 Apr; 133(4):391-7. PubMed ID: 25569026
[TBL] [Abstract][Full Text] [Related]
14. Fluorescein angiography of aggressive posterior retinopathy of prematurity treated with intravitreal anti-VEGF in large preterm babies.
Park SW; Jung HH; Heo H
Acta Ophthalmol; 2014 Dec; 92(8):810-3. PubMed ID: 24909062
[No Abstract] [Full Text] [Related]
15. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab.
Chen SN; Lian I; Hwang YC; Chen YH; Chang YC; Lee KH; Chuang CC; Wu WC
Retina; 2015 Apr; 35(4):667-74. PubMed ID: 25462435
[TBL] [Abstract][Full Text] [Related]
16. Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin).
Dorta P; Kychenthal A
Retina; 2010 Apr; 30(4 Suppl):S24-31. PubMed ID: 20224475
[TBL] [Abstract][Full Text] [Related]
17. Dramatic regression of persistent tunica vasculosa lentis associated with retinopathy of prematurity following treatment with intravitreal bevacizumab.
Goldman DR; Baumal CR
J Pediatr Ophthalmol Strabismus; 2013 Jun; 50 Online():e27-9. PubMed ID: 24601434
[TBL] [Abstract][Full Text] [Related]
18. Refractive outcome of intravitreal bevacizumab injection in comparison to spontaneous regression of retinopathy of prematurity (ROP).
Etezad Razavi M; Shoeibi N; Hassanzadeh S; Kianmehr S; Bakhtiari E
Strabismus; 2020 Mar; 28(1):49-54. PubMed ID: 31790628
[No Abstract] [Full Text] [Related]
19. Efficacy of intravitreal injection of anti-vascular endothelial growth factor agents for stage 4 retinopathy of prematurity.
Cheng HC; Lee SM; Hsieh YT; Lin PK
Retina; 2015 Apr; 35(4):660-6. PubMed ID: 25313709
[TBL] [Abstract][Full Text] [Related]
20. Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity.
Patel RD; Blair MP; Shapiro MJ; Lichtenstein SJ
Arch Ophthalmol; 2012 Jun; 130(6):801-2. PubMed ID: 22801851
[No Abstract] [Full Text] [Related]
[Next] [New Search]
